In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer.
about
Polymer-enhanced delivery increases adenoviral gene expression in an orthotopic model of bladder cancerTargeting the Fas/Fas ligand pathway in cancer.Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report.Death receptors as targets for anti-cancer therapy.Emerging apoptosis agonists for bladder cancer.A Lentiviral Vector Expressing Desired Gene Only in Transduced Cells: An Approach for Suicide Gene Therapy.A novel double-enhanced suicide gene therapy in a colon cancer cell line mediated by gef and apoptin.miR-708 promotes the development of bladder carcinoma via direct repression of Caspase-2.Efficient growth suppression and apoptosis in human laryngeal carcinoma cell line HEP-2 induced by an adeno-associated virus expressing human FAS ligand.Apigenin, a dietary flavonoid, inhibits proliferation of human bladder cancer T-24 cells via blocking cell cycle progression and inducing apoptosisFas ligand gene transfer effectively induces apoptosis in head and neck cancer cells.Isolinderanolide B, a butanolide extracted from the stems of Cinnamomum subavenium, inhibits proliferation of T24 human bladder cancer cells by blocking cell cycle progression and inducing apoptosis.Exploiting the tumor microenvironment in the development of targeted cancer gene therapy.FasL gene therapy: a new therapeutic modality for head and neck cancer.Hedgehog signaling maintains resident hepatic progenitors throughout life.Role for hedgehog signaling in hepatic stellate cell activation and viability.In vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-XL.Nanotechnology in Cancer Drug Delivery and Selective Targeting
P2860
Q35076484-7B264866-F86A-4276-AC57-6134C8FC5744Q36268329-9C90438E-C808-4D56-BB55-49A0C398F338Q36501180-1D6FC584-788B-4C96-8F69-2C9CECFC9D6AQ37390893-AD817CF5-4286-4081-BC0A-50F73B0902E1Q37601481-FE39E541-CE67-41E6-895C-94B216C54123Q38870602-B24E40B5-7609-4A79-BC09-F0A83042539EQ39114380-9CF7C1FF-AC12-4B4C-A0C4-D51E42BBF450Q39169203-DFE7C916-14BD-46F1-B8B4-FF2B835C1286Q39408042-4ABF409F-6F4C-4E79-B340-EC59F35FF06EQ39436775-0DA048AD-A4FA-421B-9A84-05BCD8BF6730Q39556274-127E33CE-7EF0-490F-A38A-D6E854F385E2Q39613200-EBA3FB52-3828-4DD8-AA83-FA608E126E0DQ39935539-8ECB463C-95ED-4B85-BC33-1A1AD25A25C6Q40303364-ECE077D7-7F2D-47DA-8BD8-23246CD3DE0AQ40345226-705F2419-12EB-4816-960E-01212E184EE6Q40371810-5C5868BD-AFE4-4AB5-AE39-9E04A0E7AC0DQ45886935-5BC73986-ACD4-4FAB-B744-C9670AC5BFD5Q59049899-D18162DD-0B6F-4B2F-8D9A-1C05121CD0E3
P2860
In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer.
@en
In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer.
@nl
type
label
In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer.
@en
In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer.
@nl
prefLabel
In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer.
@en
In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer.
@nl
P2093
P2860
P356
P1433
P1476
In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer.
@en
P2093
Christina Voelkel-Johnson
David H Holman
James S Norris
Jian-Yun Dong
Marc L Hyer
Sunil Sudarshan
P2860
P2888
P356
10.1038/SJ.CGT.7700746
P577
2005-01-01T00:00:00Z
P5875
P6179
1018649578